Summary sheet
The project supports the growth of local pharmaceutical and healthcare companies in the Southern Neighbourhood and, to a lesser extent, in Sub-Saharan Africa, through participation in a private equity fund that invests to enhance affordable access to quality disruptive technology and medical services. The project is expected to be strongly aligned with EU trade interests with many portfolio companies that are either expected to source equipment from EU-based suppliers or partner with EU pharmaceutical and MedTech companies to provide regional services.
The project supports the growth of local companies and enhances affordable access to quality healthcare products and medical services for final beneficiaries, through investments that will contribute to fulfilling the financing gap of growth capital for pharmaceutical and healthcare companies, predominantly in Northern Africa (Egypt and Morocco), and to a lower extent in Sub-Saharan Africa. This project is not only aligned with the EU-Africa Global Gateway Investment Package, reinforcing the EU's world-leading position as an innovative trade powerhouse in the life sciences and healthcare sector, but also aims to contribute to the 2030 ambition set by the EU under the EU Global Health Strategy and the EU-Africa Global Gateway Investment Package, to strengthen African pharmaceutical systems with regional manufacturing capacities to meet local needs and demand, by promoting research and cross-border innovation in healthcare. The project will support local healthcare system strengthening through private-sector investments into the equitable access to specialised clinical care. The project is expected to contribute to Northern Africa's inclusive economic growth, sustainable and resilient human development, whilst also encouraging the development of the healthcare sector and vital job creation in Northern and Sub-Saharan Africa.
The project will be implemented in line with the requirements of applicable national and EU environmental and social legislation as well as the relevant EIB Environmental and Social Standards.
The Bank will require that the project is implemented in accordance with the EIB's Guide to Procurement.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications